Please assess the completion status of the following clinical trial:

Trial Title: Imatinib as Pre-operative Anti-Colon Cancer Targeted Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female aged ≥18 years~2. Histologically proven adenocarcinoma of the colon;~3. Completed cancer staging with CT-abdomen and CT-thorax/X-thorax according to hospital's standard of care;~4. Confirmed eligibility for surgery with curative intent as deemed by the hospital's multidisciplinary board (MDB) review;~5. An intratumoural gene expression profile of PDGFR-α, PDGFR-β, PDGF-C and KIT, indicative of the mesenchymal phenotype, according to our diagnostic RT-qPCR test (i.e. more than 50% chance of having the mesenchymal phenotype);~6. Minimum of four properly stored pre-treatment biopsies for gene expression analysis/ELISA;~7. WHO performance status 0 or 1;~8. Adequate haematology status and organ function, defined as:~   * Normal creatinine clearance (≥60 ml/min (MRDR))~  * ALAT within 2.5x upper limit of normal (ULN)~  * PT-INR \< 1.5~  * Leukocytes \> 1,5\*10\^9/L; Hb \> 6.0 mmol/L; platelets \> 100\*10\^9/L~9. Willingness and ability to comply with scheduled visits, treatment plans and laboratory tests;~10. Written informed consent.~Exclusion Criteria:~1. The presence of synchronous distant metastases;~2. Current hospital standard of care dictates that subject should undergo any neoadjuvant therapy;~3. Concurrent participation in another clinical trial using any medicinal product, or participation in such a trial in the period of three months prior to the current trial;~4. Women who are pregnant, plan to become pregnant or are lactating during the study or for up to 30 days after the last dose of imatinib;~5. Known HIV or Hepatitis B/C infection;~6. Known symptomatic congestive heart failure;~7. Co-morbidity requiring concomitant treatment with drugs that act as strong inducers of CYP3A4 or with drugs with a narrow therapeutic range influenced by imatinib

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): Subjects will be treated with the medicinal product imatinib, which will be administered orally in tablets of 400mg, once per day, during two weeks prior to tumor resection.

Based on this trial design, predict the completion outcome and termination type (if applicable).